A Phase 1 interventional study of RSVpreF+qIRV and qIRV in Healthy, sponsored by Pfizer. Completed at 1 site in Argentina. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.
Sponsored by Pfizer · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.
Among the 15 studies in Influenza, Human by Pfizer, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 1, and was the 8th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2007; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 508 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 882 across the 11 interventional studies, 5,075 across the 4 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Influenza, Human by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
| NCT07431853PfizerA Study to Learn About mRNA Vaccines Against Influenza in Adults | 2027-06-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Influenza, Human by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Substudy A: The study aims to learn about the safety and effects of two new vaccines for RSV (RSVpreF) and influenza (modRNA qIRV) when given as a single shot compared to when given separately. RSV and influenza lead to infections, mainly in the fall and winter. These vaccines are being developed to help prevent respiratory syncytial virus (RSV) and influenza (Flu) disease.
This study is seeking participants who:
The participants will be divided into 2 groups. Group 1 will receive RSVpreF plus qIRV combo shot, after which participants will receive the placebo (a shot which has no medicine). Group 2 will receive shots for qIRV first and then RSVpreF 1 month apart.
The investigators will examine the experiences of the participants receiving the study vaccines. This will help the investigators determine if the study vaccines are safe and produce a similar immune response.
Participants will be involved in this study for 2 months. During this time, participants will have 3 visits at the study clinic.
Substudy B will investigate 2 formulations of RSVpreF + qIRV of different volumes and osmolaities (concentrations). These formulations will be examined for safety, tolerability, and immunogenicity, with the goal of selecting a formulation for further study.
This study is seeking participants who:
The participants will be divided into 2 groups. Group 1 will receive RSVpreF plus qIRV in a 1.0-mL formulation while Group 2 will receive RSVpreF plus qIRV in a 0.5-mL formulation.
The investigators will examine the experiences of the participants receiving the study vaccines. This will help the investigators determine if the study vaccines are safe, well tolerated and produce a similar immune response.
Participants will be involved in this study for 1 month. During this time, participants will have 2 visits at the study clinic.
Substudy A: This study is designed to evaluate the safety, tolerability, and immunogenicity of respiratory combination vaccine candidates. This initial study will be conducted as a Phase 1b, parallel-group, randomized, placebo-controlled, observer-blinded substudy of RSVpreF and a nucleoside-modified RNA vaccine (qIRV) against RSV and influenza when administered as a combined vaccine and when administered alone.
Healthy adults ≥60 years of age will be randomized 1:1 to either Group 1: combination (RSVpreF + qIRV) followed by placebo; or Group 2: sequential administration of qIRV followed by RSVpreF administered 1 month apart.
Substudy B will be conducted as a Phase 1b, parallel-group, randomized, observer-blinded substudy of RSVpreF and a nucleoside-modified RNA vaccine (qIRV) against RSV and influenza administered as a combined vaccine in a 1.0-mL formulation and when administered in a 0.5-mL formulation.
Healthy adults ≥50 years of age will be randomized 1:1 to either Group 1: combination (RSVpreF + qIRV) 1.0-mL formulation; or Group 2: combination (RSVpreF + qIRV) 0.5 mL formulation. Approximately 100 participants will be randomized within the 50- through 64-year-old group, and 100 participants ≥65 years of age will be randomized.
Substudy A:
Inclusion Criteria:
Exclusion Criteria:
Substudy B
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination (RSVpreF + qIRV) (Visit 1) followed by placebo (Visit 2). RSVpreF and qIRV are administered as concomitantly but as individual injections.
Biological: RSVpreF+qIRV · Drug: Placebo
Sequential administration of qIRV (Visit 1) followed by RSVpreF (Visit 2)
Biological: qIRV · Biological: RSVpreF
RSVpreF lyophilized cake reconstituted with water for injection and mixed with qIRV, yielding an injection volume of 1.0 mL
Biological: RSVpreF + qIRV 1.0 mL formulation
RSVpreF lyophilized cake reconstituted with qIRV to yield an injection volume of 0.5 mL
Biological: RSVpreF + qIRV 1.0 mL formulation · Biological: RSVpreF + qIRV 0.5 mL formulation
RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
Also known as: PF-07252220
RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
Also known as: PF-06928316
0.9% saline for injection
RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
Also known as: PF-07941314
RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
Also known as: PF-07941314
SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: greater than (\>) 5.0 cm to 10.0 cm; severe: \> 10 cm.
Time frame: SSA: From Day 1 to Day 7 after Vaccination 1
SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm; severe: \> 10 cm.
Time frame: SSA: From Day 1 to Day 7 after Vaccination 2 (1 Month After Vaccination 1)
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm; severe: \> 10 cm.
Time frame: SSB: From Day 1 to Day 7 after Vaccination
SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: SSA: From Day 1 to Day 7 after Vaccination 1
SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 deg C and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24h; moderate: \>2 times in 24h; severe: required IV hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: SSA: From Day 1 to Day 7 after Vaccination 2 (1 Month after Vaccination 1)
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 deg C and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24h; moderate: \>2 times in 24h; severe: required IV hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: SSB: From Day 1 to Day 7 After Vaccination
SSA: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 1
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
Time frame: SSA: Within 1 Month after Vaccination 1
SSA: Percentage of Participants Reporting AEs Within 1 Month After Vaccination 2
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
Time frame: SSA: Within 1 Month after Vaccination 2
SSB: Percentage of Participants Reporting AEs Throughout the Sub Study
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
Time frame: SSB: From Day 1 of Vaccination up to 35 days of follow-up post Vaccination
SSA: Percentage of Participants Reporting Serious Adverse Events (SAEs) Throughout the Sub Study
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event.
Time frame: SSA: From Day 1 (Vaccination 1) up to 35 days of follow-up post Vaccination 2 (Maximum up to 70 days)
SSB: Percentage of Participants Reporting SAEs Throughout the Sub Study
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event.
Time frame: SSB: From Day 1 of Vaccination up to 35 days of follow-up post Vaccination (Maximum up to 36 days)
SSA: Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Neutralizing Titers (NT) for Each RSV Subgroup (A or B) 1 Month After Vaccination With Combination RSVpreF + qIRV (Group 1) and RSVpreF Alone (Group 2)
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of RSV subgroup A (RSV A) or RSV subgroup B (RSV B) neutralizing GMTs in the combination RSVpreF + qIRV group to that in the sequential-administration RSVpreF group.
Time frame: SSA- For Group 1: 1 Month after Vaccination 1 (Day 1); For Group 2: 1 Month after Vaccination 2 (1 Month after Vaccination 1)
SSA: GMT and GMR of Strain-Specific Hemagglutination Inhibition (HAI) Titers For 1 Month After Vaccination With Combination RSVpreF + qIRV (Group 1) and qIRV Alone (Group 2)
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of each strain neutralizing GMTs in the combination RSVpreF + qIRV group to that in the sequential-administration RSVpreF group. The analysis was performed on the influenza strains: H1N1 A/Sydney, H3N2 A/Darwin, B/Austria, and B/Phuket.
Time frame: SSA- For Group 1: 1 Month after Vaccination 1 (Day 1); For Group 2: 1 Month after Vaccination 2 (1 Month after Vaccination 1)
SSB: GMT and GMR of NT for Each RSV A or RSV B 1 Month After Vaccination
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of RSV A or RSV B neutralizing GMTs in the combination of 1 mL RSVpreF + qIRV (group 1) and 0.5 ml of RSVpreF + qIRV (group 2)
Time frame: SSB: At 1 Month after Vaccination (Day 1)
SSB: GMTs of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After Vaccination
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of each strain neutralizing GMTs to the combination of 1 mL RSVpreF + qIRV (Group 1) and 0.5 ml of RSVpreF + qIRV (Group 2). The analysis was performed on the influenza strains: H1N1 A/Sydney, H3N2 A/Darwin, B/Austria, and B/Phuket.
Time frame: SSB: At 1 Month after Vaccination (Day 1)
This study had sub-study A (SSA) and sub-study B (SSB).
| Milestone | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|---|---|
| Started | 125 | 126 | 0 | 0 |
| Vaccination 1 | 125 | 126 | 0 | 0 |
| Vaccination 2 | 121 | 116 | 0 | 0 |
| Completed | 120 | 113 | 0 | 0 |
| Not completed | 5 | 13 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 8 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Milestone | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|---|---|
| Started | 0 | 0 | 102 | 102 |
| Vaccination | 0 | 0 | 101 | 102 |
| Completed | 0 | 0 | 101 | 100 |
| Not completed | 0 | 0 | 1 | 2 |
| Withdrew: Not vaccinated | 0 | 0 | 1 | 0 |
| Withdrew: Refused further study procedures | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: greater than (\>) 5.0 cm to 10.0 cm; severe: \> 10 cm.
| Percentage of participants | SSA: Group 1: RSVpreF + qIRV | SSA: Group 2: qIRV |
|---|---|---|
| Pain at the injection site: Mild | 49.6 (40.5 to 58.7) | 52.0 (42.9 to 61.0) |
| Pain at the injection site: Moderate | 20.8 (14.1 to 29.0) | 28.0 (20.3 to 36.7) |
| Pain at the injection site: Severe | 0 (0.0 to 2.9) | 2.4 (0.5 to 6.9) |
| Redness: Mild | 3.2 (0.9 to 8.0) | 3.2 (0.9 to 8.0) |
| Redness: Moderate | 4.0 (1.3 to 9.1) | 4.8 (1.8 to 10.2) |
| Redness: Severe | 0 (0.0 to 2.9) | 0.8 (0.0 to 4.4) |
| Swelling: Mild | 5.6 (2.3 to 11.2) | 6.4 (2.8 to 12.2) |
| Swelling: Moderate | 3.2 (0.9 to 8.0) | 8.0 (3.9 to 14.2) |
| Swelling: Severe | 0.8 (0.0 to 4.4) | 2.4 (0.5 to 6.9) |
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm; severe: \> 10 cm.
| Percentage of participants | SSA: Group 1: Placebo | SSA: Group 2: RSVpreF |
|---|---|---|
| Pain at the injection site: Mild | 1.7 (0.2 to 5.8) | 7.8 (3.6 to 14.3) |
| Pain at the injection site: Moderate | 1.7 (0.2 to 5.8) | 0.9 (0.0 to 4.7) |
| Pain at the injection site: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Redness: Mild | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Redness: Moderate | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Redness: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Swelling: Mild | 0.8 (0.0 to 4.5) | 0.9 (0.0 to 4.7) |
| Swelling: Moderate | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Swelling: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity; severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: 2.5 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm; severe: \> 10 cm.
| Percentage of participants | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| Pain at the injection site: Mild | 42.6 (32.8 to 52.8) | 43.1 (33.4 to 53.3) |
| Pain at the injection site: Moderate | 31.7 (22.8 to 41.7) | 32.4 (23.4 to 42.3) |
| Pain at the injection site: Severe | 1.0 (0.0 to 5.4) | 2.9 (0.6 to 8.4) |
| Redness: Mild | 2.0 (0.2 to 7.0) | 2.0 (0.2 to 6.9) |
| Redness: Moderate | 0 (0.0 to 3.6) | 3.9 (1.1 to 9.7) |
| Redness: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.6) |
| Swelling: Mild | 4.0 (1.1 to 9.8) | 5.9 (2.2 to 12.4) |
| Swelling: Moderate | 5.9 (2.2 to 12.5) | 7.8 (3.4 to 14.9) |
| Swelling: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.6) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSA: Group 1: RSVpreF + qIRV | SSA: Group 2: qIRV |
|---|---|---|
| Fever: Mild | 4.0 (1.3 to 9.1) | 12.8 (7.5 to 20.0) |
| Fever: Moderate | 6.4 (2.8 to 12.2) | 4.0 (1.3 to 9.1) |
| Fever: Severe | 1.6 (0.2 to 5.7) | 5.6 (2.3 to 11.2) |
| Fatigue: Mild | 20.8 (14.1 to 29.0) | 20.8 (14.1 to 29.0) |
| Fatigue: Moderate | 30.4 (22.5 to 39.3) | 24.0 (16.8 to 32.5) |
| Fatigue: Severe | 0.8 (0.0 to 4.4) | 4.0 (1.3 to 9.1) |
| Headache: Mild | 24.0 (16.8 to 32.5) | 26.4 (18.9 to 35.0) |
| Headache: Moderate | 24.8 (17.5 to 33.3) | 11.2 (6.3 to 18.1) |
| Headache: Severe | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Vomiting: Mild | 1.6 (0.2 to 5.7) | 1.6 (0.2 to 5.7) |
| Vomiting: Moderate | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Vomiting: Severe | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Nausea: Mild | 5.6 (2.3 to 11.2) | 5.6 (2.3 to 11.2) |
| Nausea: Moderate | 2.4 (0.5 to 6.9) | 3.2 (0.9 to 8.0) |
| Nausea: Severe | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Diarrhea: Mild | 4.8 (1.8 to 10.2) | 4.0 (1.3 to 9.1) |
| Diarrhea: Moderate | 1.6 (0.2 to 5.7) | 1.6 (0.2 to 5.7) |
| Diarrhea: Severe | 0.8 (0.0 to 4.4) | 0 (0.0 to 2.9) |
| Chills: Mild | 15.2 (9.4 to 22.7) | 20.8 (14.1 to 29.0) |
| Chills: Moderate | 12.0 (6.9 to 19.0) | 11.2 (6.3 to 18.1) |
| Chills: Severe | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| New or worsened muscle pain: Mild | 17.6 (11.4 to 25.4) | 20.8 (14.1 to 29.0) |
| New or worsened muscle pain: Moderate | 22.4 (15.4 to 30.7) | 15.2 (9.4 to 22.7) |
| New or worsened muscle pain: Severe | 0 (0.0 to 2.9) | 1.6 (0.2 to 5.7) |
| New or worsened joint pain: Mild | 11.2 (6.3 to 18.1) | 11.2 (6.3 to 18.1) |
| New or worsened joint pain: Moderate | 14.4 (8.8 to 21.8) | 6.4 (2.8 to 12.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 2.9) | 0.8 (0.0 to 4.4) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 deg C and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24h; moderate: \>2 times in 24h; severe: required IV hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSA: Group 1: Placebo | SSA: Group 2: RSVpreF |
|---|---|---|
| Fever: Mild | 0 (0.0 to 3.0) | 0.9 (0.0 to 4.7) |
| Fever: Moderate | 0 (0.0 to 3.0) | 0.9 (0.0 to 4.7) |
| Fever: Severe | 0 (0.0 to 3.0) | 0.9 (0.0 to 4.7) |
| Fatigue: Mild | 7.4 (3.5 to 13.7) | 6.1 (2.5 to 12.1) |
| Fatigue: Moderate | 3.3 (0.9 to 8.2) | 7.0 (3.1 to 13.2) |
| Fatigue: Severe | 0 (0.0 to 3.0) | 1.7 (0.2 to 6.1) |
| Headache: Mild | 10.7 (5.8 to 17.7) | 10.4 (5.5 to 17.5) |
| Headache: Moderate | 5.8 (2.4 to 11.6) | 6.1 (2.5 to 12.1) |
| Headache: Severe | 0 (0.0 to 3.0) | 0.9 (0.0 to 4.7) |
| Vomiting: Mild | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Vomiting: Moderate | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Vomiting: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Nausea: Mild | 3.3 (0.9 to 8.2) | 1.7 (0.2 to 6.1) |
| Nausea: Moderate | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Nausea: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Diarrhea: Mild | 5.0 (1.8 to 10.5) | 2.6 (0.5 to 7.4) |
| Diarrhea: Moderate | 1.7 (0.2 to 5.8) | 0.9 (0.0 to 4.7) |
| Diarrhea: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| Chills: Mild | 2.5 (0.5 to 7.1) | 3.5 (1.0 to 8.7) |
| Chills: Moderate | 1.7 (0.2 to 5.8) | 2.6 (0.5 to 7.4) |
| Chills: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| New or worsened muscle pain: Mild | 5.8 (2.4 to 11.6) | 4.3 (1.4 to 9.9) |
| New or worsened muscle pain: Moderate | 1.7 (0.2 to 5.8) | 7.0 (3.1 to 13.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
| New or worsened joint pain: Mild | 4.1 (1.4 to 9.4) | 2.6 (0.5 to 7.4) |
| New or worsened joint pain: Moderate | 1.7 (0.2 to 5.8) | 6.1 (2.5 to 12.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 3.0) | 0 (0.0 to 3.2) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, chills, new/worsened muscle pain and new/worsened joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 deg C and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24h; moderate: \>2 times in 24h; severe: required IV hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and new/worsened joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| Fever: Mild | 15.8 (9.3 to 24.4) | 10.8 (5.5 to 18.5) |
| Fever: Moderate | 4.0 (1.1 to 9.8) | 2.0 (0.2 to 6.9) |
| Fever: Severe | 2.0 (0.2 to 7.0) | 0 (0.0 to 3.6) |
| Fatigue: Mild | 20.8 (13.4 to 30.0) | 28.4 (19.9 to 38.2) |
| Fatigue: Moderate | 36.6 (27.3 to 46.8) | 26.5 (18.2 to 36.1) |
| Fatigue: Severe | 0 (0.0 to 3.6) | 5.9 (2.2 to 12.4) |
| Headache: Mild | 18.8 (11.7 to 27.8) | 26.5 (18.2 to 36.1) |
| Headache: Moderate | 27.7 (19.3 to 37.5) | 15.7 (9.2 to 24.2) |
| Headache: Severe | 0 (0.0 to 3.6) | 2.0 (0.2 to 6.9) |
| Vomiting: Mild | 0 (0.0 to 3.6) | 2.0 (0.2 to 6.9) |
| Vomiting: Moderate | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.3) |
| Vomiting: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.6) |
| Nausea: Mild | 5.0 (1.6 to 11.2) | 11.8 (6.2 to 19.6) |
| Nausea: Moderate | 4.0 (1.1 to 9.8) | 2.9 (0.6 to 8.4) |
| Nausea: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.6) |
| Diarrhea: Mild | 9.9 (4.9 to 17.5) | 10.8 (5.5 to 18.5) |
| Diarrhea: Moderate | 5.9 (2.2 to 12.5) | 2.9 (0.6 to 8.4) |
| Diarrhea: Severe | 0 (0.0 to 3.6) | 0 (0.0 to 3.6) |
| Chills: Mild | 15.8 (9.3 to 24.4) | 17.6 (10.8 to 26.4) |
| Chills: Moderate | 24.8 (16.7 to 34.3) | 13.7 (7.7 to 22.0) |
| Chills: Severe | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.3) |
| New or worsened muscle pain: Mild | 18.8 (11.7 to 27.8) | 21.6 (14.0 to 30.8) |
| New or worsened muscle pain: Moderate | 27.7 (19.3 to 37.5) | 22.5 (14.9 to 31.9) |
| New or worsened muscle pain: Severe | 2.0 (0.2 to 7.0) | 1.0 (0.0 to 5.3) |
| New or worsened joint pain: Mild | 14.9 (8.6 to 23.3) | 11.8 (6.2 to 19.6) |
| New or worsened joint pain: Moderate | 20.8 (13.4 to 30.0) | 16.7 (10.0 to 25.3) |
| New or worsened joint pain: Severe | 0 (0.0 to 3.6) | 1.0 (0.0 to 5.3) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
| Percentage of participants | SSA: Group 1: RSVpreF + qIRV | SSA: Group 2: qIRV |
|---|---|---|
| SSA: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 1 | 29.6 (21.8 to 38.4) | 33.3 (25.2 to 42.3) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
| Percentage of participants | SSA: Group 1: Placebo | SSA: Group 2: RSVpreF |
|---|---|---|
| SSA: Percentage of Participants Reporting AEs Within 1 Month After Vaccination 2 | 16.5 (10.4 to 24.4) | 13.8 (8.1 to 21.4) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included.
| Percentage of participants | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| SSB: Percentage of Participants Reporting AEs Throughout the Sub Study | 22.8 (15.0 to 32.2) | 33.3 (24.3 to 43.4) |
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event.
| Percentage of participants | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF |
|---|---|---|
| SSA: Percentage of Participants Reporting Serious Adverse Events (SAEs) Throughout the Sub Study | 0 (0.0 to 2.9) | 2.4 (0.5 to 6.8) |
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event.
| Percentage of participants | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| SSB: Percentage of Participants Reporting SAEs Throughout the Sub Study | 2.0 (0.2 to 7.0) | 0 (0.0 to 3.6) |
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of RSV subgroup A (RSV A) or RSV subgroup B (RSV B) neutralizing GMTs in the combination RSVpreF + qIRV group to that in the sequential-administration RSVpreF group.
| Titer | SSA: Group 1: Combination RSVpreF + qIRV | SSA: Group 2: Sequential Administration RSVpreF Alone |
|---|---|---|
| NT: RSV A | 16553 (14120.9 to 19403.1) | 19740 (16555.5 to 23536.4) |
| NT: RSV B | 11795 (9961.1 to 13966.7) | 14959 (12408.8 to 18032.4) |
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of each strain neutralizing GMTs in the combination RSVpreF + qIRV group to that in the sequential-administration RSVpreF group. The analysis was performed on the influenza strains: H1N1 A/Sydney, H3N2 A/Darwin, B/Austria, and B/Phuket.
| Titer | SSA: Group 1: Combination RSVpreF + qIRV | SSA: Group 2: Sequential Administration RSVpreF Alone |
|---|---|---|
| HAI: H1N1 A/Wisconsin | 194 (164.3 to 227.9) | 238 (196.5 to 288.7) |
| HAI: H3N2 A/Darwin | 161 (136.9 to 189.9) | 219 (178.1 to 269.0) |
| HAI: B/Austria | 53 (44.6 to 62.1) | 56 (47.7 to 66.3) |
| HAI: B/Phuket | 22 (18.5 to 26.4) | 24 (20.2 to 29.1) |
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of RSV A or RSV B neutralizing GMTs in the combination of 1 mL RSVpreF + qIRV (group 1) and 0.5 ml of RSVpreF + qIRV (group 2)
| Titer | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| NT: RSV A | 32044 (26676.5 to 38492.2) | 30575 (25922.1 to 36062.4) |
| NT: RSV B | 30364 (25533.4 to 36108.2) | 28614 (24113.5 to 33954.8) |
GMTs and associated 2-sided 95% CIs are reported as descriptive data. GMRs and associated 2-sided 95% CIs are reported in statistical analysis section of this outcome measure. GMR was the ratio of each strain neutralizing GMTs to the combination of 1 mL RSVpreF + qIRV (Group 1) and 0.5 ml of RSVpreF + qIRV (Group 2). The analysis was performed on the influenza strains: H1N1 A/Sydney, H3N2 A/Darwin, B/Austria, and B/Phuket.
| Titer | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|
| HAI: H1N1 A/Sydney | 257 (212.6 to 311.8) | 217 (170.2 to 275.8) |
| HAI: H3N2 A/Darwin | 259 (216.4 to 310.8) | 229 (188.7 to 279.0) |
| HAI: B/Austria | 58 (49.0 to 69.0) | 54 (45.0 to 64.1) |
| HAI: B/Phuket | 32 (27.0 to 38.6) | 29 (25.1 to 34.4) |
Collected over Local reactions/systemic events (systematic assessment): Day 1 up to Day 7 after each Vaccination; AEs (non-systematic assessment): SSA- Day 1 up to 35 days after Vaccination 2 (Maximum up to approximately 70 days) and SSB- Day 1 up to 35 days after Vaccination (Maximum up to approximately 36 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SSA: Group 1: RSVpreF + qIRV | 0/125 (0%) | 0/125 (0%) | 117/125 (93.6%) |
| SSA: Group 1: Placebo | 0/121 (0%) | 0/121 (0%) | 50/121 (41.3%) |
| SSA: Group 2: qIRV | 0/126 (0%) | 1/126 (0.8%) | 117/126 (92.9%) |
| SSA: Group 2: RSVpreF | 1/116 (0.9%) | 1/116 (0.9%) | 43/116 (37.1%) |
| SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | 0/101 (0%) | 2/101 (2%) | 91/101 (90.1%) |
| SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation | 0/102 (0%) | 0/102 (0%) | 96/102 (94.1%) |
| Event | SSA: Group 1: RSVpreF + qIRV | SSA: Group 1: Placebo | SSA: Group 2: qIRV | SSA: Group 2: RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/125 | 0/121 | 0/126 | 0/116 | 1/101 | 0/102 |
| Haemorrhage intracranialNervous system disorders | 0/125 | 0/121 | 0/126 | 0/116 | 1/101 | 0/102 |
| Cardiac arrestCardiac disorders | 0/125 | 0/121 | 0/126 | 1/116 | 0/101 | 0/102 |
| Cardiac failureCardiac disorders | 0/125 | 0/121 | 0/126 | 1/116 | 0/101 | 0/102 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/125 | 0/121 | 0/126 | 1/116 | 0/101 | 0/102 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/125 | 0/121 | 1/126 | 0/116 | 0/101 | 0/102 |
| SyncopeNervous system disorders | 0/125 | 0/121 | 1/126 | 0/116 | 0/101 | 0/102 |
| Event | SSA: Group 1: RSVpreF + qIRV | SSA: Group 1: Placebo | SSA: Group 2: qIRV | SSA: Group 2: RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation |
|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT THE INJECTION SITE)General disorders | 88/125 | 4/121 | 103/125 | 10/115 | 76/101 | 80/102 |
| Fatigue (FATIGUE)General disorders | 65/125 | 13/121 | 61/125 | 17/115 | 58/101 | 62/102 |
| Headache (HEADACHE)Nervous system disorders | 61/125 | 20/121 | 47/125 | 20/115 | 47/101 | 45/102 |
| Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 50/125 | 9/121 | 47/125 | 13/115 | 49/101 | 46/102 |
| Chills (CHILLS)General disorders | 34/125 | 5/121 | 40/125 | 7/115 | 41/101 | 33/102 |
| Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders | 32/125 | 7/121 | 23/125 | 10/115 | 36/101 | 30/102 |
| Pyrexia (FEVER)General disorders | 15/125 | 0/121 | 28/125 | 3/115 | 22/101 | 13/102 |
| Injection site swelling (SWELLING)General disorders | 12/125 | 1/121 | 21/125 | 1/115 | 10/101 | 14/102 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 9/125 | 8/121 | 7/125 | 4/115 | 16/101 | 14/102 |
| Nausea (NAUSEA)Gastrointestinal disorders | 10/125 | 4/121 | 11/125 | 2/115 | 9/101 | 15/102 |
Safety population was evaluated. SSA= All enrolled participants who received the study intervention either in combination RSVpreF + qIRV, or as placebo, qIRV, or RSVpreF alone. SSB= All enrolled participants who received the study intervention (0.5 mL or 1.0 mL).
| Age, Customized(Participants) | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation | Total |
|---|---|---|---|---|---|
| 50-64 years | 22 | 23 | 50 | 52 | 147 |
| 65-79 years | 94 | 93 | 48 | 47 | 282 |
| >=80 years | 9 | 10 | 3 | 3 | 25 |
| Sex: Female, Male(Participants) | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation | Total |
|---|---|---|---|---|---|
| Female | 62 | 73 | 47 | 48 | 230 |
| Male | 63 | 53 | 54 | 54 | 224 |
| Ethnicity (NIH/OMB)(Participants) | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 125 | 126 | 101 | 101 | 453 |
| Not Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SSA: Group 1: Combination (RSVpreF + qIRV)/ Placebo | SSA: Group 2: Sequential Administration qIRV/ RSVpreF | SSB: Group 1: RSVpreF + qIRV 1.0 mL Formulation | SSB: Group 2: RSVpreF + qIRV 0.5 mL Formulation | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 125 | 126 | 101 | 102 | 454 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Mar 2023 to primary completion in Sep 2023, 6 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo